Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Revenue	$ 5,422	$ 183	$ 16,578	$ 3,713
Cost of revenue	4,249	921	10,536	3,227
Gross profit (loss)	1,173	(738)	6,042	486
Operating Expenses (Income)
Research and development	4,838	4,889	15,384	16,814
Sales and marketing	5,819	4,528	17,835	12,000
General and administrative	3,686	2,920	9,989	8,688
Amortization of intangible assets	2,674	1,821	8,244	5,144
Change in fair value of contingent consideration	(1,358)	773	81	1,226
Issuance costs for warrants				627
Acquisition related costs	345		345
Gain from sale of SurgiBot assets, net	44		(11,915)
Reversal of transfer fee accrual	(2,994)		(2,994)
Total Operating Expenses (Income)	13,054	14,931	36,969	44,499
Operating Loss	(11,881)	(15,669)	(30,927)	(44,013)
Other (Expense) Income
Change in fair value of warrant liabilities	(8,760)	(22,887)	(24,438)	(25,213)
Interest income	391	62	982	124
Interest expense	(685)	(563)	(3,398)	(1,581)
Other expense	(52)	(194)	(109)	(294)
Total Other (Expense) Income, net	(9,106)	(23,582)	(26,963)	(26,964)
Loss before income taxes	(20,987)	(39,251)	(57,890)	(70,977)
Income tax benefit	781	738	2,554	2,337
Net loss	(20,206)	(38,513)	(55,336)	(68,640)
Other comprehensive loss
Foreign currency translation (loss) gain	(561)	2,952	(2,651)	9,515
Comprehensive loss	$ (20,767)	$ (35,561)	$ (57,987)	$ (59,125)
Net loss per share - basic and diluted	$ (0.10)	$ (0.26)	$ (0.27)	$ (0.51)
Weighted average common shares outstanding - basic and diluted	209,088	149,516	204,531	134,622